FcγRIIb blockage: a promising immunotherapy target for severe COVID-19

Signal Transduct Target Ther. 2021 Apr 9;6(1):147. doi: 10.1038/s41392-021-00590-8.

Authors

Xuemei He¹, Manni Wang¹, Min Wu²

Affiliations

¹ Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.
² Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA. min.wu@und.edu.

No abstract available

Publication types

Comment

MeSH terms

COVID-19*
Humans
Immunologic Factors
Immunotherapy
Receptors, IgG
SARS-CoV-2

Substances

Immunologic Factors
Receptors, IgG